The effects of single ‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

ConclusionsBococizumab was generally safe and well‐tolerated. Bococizumab lowered LDL‐C levels substantially in all four studies.This article is protected by copyright. All rights reserved.

Source: Cardiovascular Therapeutics - October 27, 2017 Category: Cardiology Authors: Barry Gumbiner, Tenshang Joh, Hong Liang, Hong Wan, Matteo Levisetti, Alicia M. Vana, David L. Shelton, Philippe Forgues, Stephan Billotte, Jaume Pons, Charles M. Baum, Pamela D. Garzone Tags: Original Research Article Source Type: research